Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Reinhard Dummer

Showing results (51-60 of 743) with videos related to

Pageof 75
Sort By:
Methods in Molecular Biology (Clifton, N.J.)|February 3, 2019
Serum S100B Levels in MelanomaAnna Lisa Frauchiger, Reinhard Dummer, Joanna Mangana
Laser Therapy|September 14, 2020
Iatrogenic tattoos after acupuncture: successful outcome after treatment with QS Ruby Laser: A case report and review of literatureCorinne Dc Eggenschwiler, Reinhard Dummer, Laurence Imhof
JAMA Oncology|January 25, 2019
Rapidly Evolving Extensive Fluorodeoxyglucose-Positive Soft-Tissue Activity During Nivolumab TherapyJoanna Mangana, Caroline S Buset, Reinhard Dummer
Oncotarget|December 30, 2021
Using drug scheduling to manage adverse events associated with hedgehog pathway inhibitors for basal cell carcinomaJohn T Lear, Reinhard Dummer, Alexander Guminski
Pigment Cell & Melanoma Research|October 17, 2015
Perturbing resistance: a network perspectiveMitchell P Levesque, Reinhard Dummer, Niko Beerenwinkel
Expert Opinion on Pharmacotherapy|August 19, 2016
Sonidegib for the treatment of advanced basal cell carcinomaEgle Ramelyte, Valerie C Amann, Reinhard Dummer
Dermatology (Basel, Switzerland)|August 28, 2025
X-Ray therapy of Skin Cancer at Critical Facial Sites: Results of a tertiary referral centreSophie Tschopp, Amélie Ciernik, Reinhard Dummer, et al.
Dermatology (Basel, Switzerland)|November 13, 2004
Successful treatment of recalcitrant chronic actinic dermatitis with tacrolimusChristian Schuster, Karoline Zepter, Werner Kempf, et al.
Swiss Medical Weekly|September 17, 2015
Data mining The Cancer Genome Atlas in the era of precision cancer medicinePhil F Cheng, Reinhard Dummer, Mitchell P Levesque
Blood|November 1, 2003
Primary cutaneous CD8+ and CD56+ T-cell lymphomas express HLA-G and killer-cell inhibitory ligand, ILT2Mirjana Urosevic, Jivko Kamarashev, Günter Burg, et al.
Pageof 75

Showing results (51-60 of 743) with videos related to

Sort By:
Pageof 75
Methods in Molecular Biology (Clifton, N.J.)|February 3, 2019
Serum S100B Levels in MelanomaAnna Lisa Frauchiger, Reinhard Dummer, Joanna Mangana
Laser Therapy|September 14, 2020
Iatrogenic tattoos after acupuncture: successful outcome after treatment with QS Ruby Laser: A case report and review of literatureCorinne Dc Eggenschwiler, Reinhard Dummer, Laurence Imhof
JAMA Oncology|January 25, 2019
Rapidly Evolving Extensive Fluorodeoxyglucose-Positive Soft-Tissue Activity During Nivolumab TherapyJoanna Mangana, Caroline S Buset, Reinhard Dummer
Oncotarget|December 30, 2021
Using drug scheduling to manage adverse events associated with hedgehog pathway inhibitors for basal cell carcinomaJohn T Lear, Reinhard Dummer, Alexander Guminski
Pigment Cell & Melanoma Research|October 17, 2015
Perturbing resistance: a network perspectiveMitchell P Levesque, Reinhard Dummer, Niko Beerenwinkel
Expert Opinion on Pharmacotherapy|August 19, 2016
Sonidegib for the treatment of advanced basal cell carcinomaEgle Ramelyte, Valerie C Amann, Reinhard Dummer
Dermatology (Basel, Switzerland)|August 28, 2025
X-Ray therapy of Skin Cancer at Critical Facial Sites: Results of a tertiary referral centreSophie Tschopp, Amélie Ciernik, Reinhard Dummer, et al.
Dermatology (Basel, Switzerland)|November 13, 2004
Successful treatment of recalcitrant chronic actinic dermatitis with tacrolimusChristian Schuster, Karoline Zepter, Werner Kempf, et al.
Swiss Medical Weekly|September 17, 2015
Data mining The Cancer Genome Atlas in the era of precision cancer medicinePhil F Cheng, Reinhard Dummer, Mitchell P Levesque
Blood|November 1, 2003
Primary cutaneous CD8+ and CD56+ T-cell lymphomas express HLA-G and killer-cell inhibitory ligand, ILT2Mirjana Urosevic, Jivko Kamarashev, Günter Burg, et al.
Pageof 75